Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation‐driven, global pharmaceutical company, is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.
AKYNZEO® I.V. is a fixed-dose combination off osnetupitant (235 mg) and palonosetron (0.25 mg). The drug is already being marketed in the EU, the US, and Australia. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle.
Glenmark is the first and only CINV prevention therapy to prevent both acute and delayed phases of cancer by a single dose. Subsequently in 2018, Glenmark launched AKYNZEO® Oral Capsules, which are the first oral treatment for cancer with a single injection.National Cancer Registry Programme data shows that cancer cases in the country are projected to rise by 12.8% by 2025 from 13.9 lakh cases in 2020. Helsinn is a third-generation family-owned company that since 1976 has been focused on improving the lives of patients, guided by core values of respect, integrity and quality. Helsinn Group CEO, Giorgio Calderari, said, “We are delighted to partner with Glenmark who has an excellent footprint in this region and is trusted with providing the best treatment options for cancer patients.”
